These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24737138)

  • 1. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.
    Kale AJ; McGlinchey RP; Lechner A; Moore BS
    ACS Chem Biol; 2011 Nov; 6(11):1257-64. PubMed ID: 21882868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
    Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
    Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
    J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
    Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
    Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
    Williamson MJ; Blank JL; Bruzzese FJ; Cao Y; Daniels JS; Dick LR; Labutti J; Mazzola AM; Patil AD; Reimer CL; Solomon MS; Stirling M; Tian Y; Tsu CA; Weatherhead GS; Zhang JX; Rolfe M
    Mol Cancer Ther; 2006 Dec; 5(12):3052-61. PubMed ID: 17172407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
    Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
    Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
    Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.
    Ahn KS; Sethi G; Chao TH; Neuteboom ST; Chaturvedi MM; Palladino MA; Younes A; Aggarwal BB
    Blood; 2007 Oct; 110(7):2286-95. PubMed ID: 17609425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
    J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
    Ruiz S; Krupnik Y; Keating M; Chandra J; Palladino M; McConkey D
    Mol Cancer Ther; 2006 Jul; 5(7):1836-43. PubMed ID: 16891470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
    Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
    Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
    Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
    Fuchs O; Provaznikova D; Marinov I; Kuzelova K; Spicka I
    Cardiovasc Hematol Disord Drug Targets; 2009 Mar; 9(1):62-77. PubMed ID: 19275578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome.
    Reed KA; Manam RR; Mitchell SS; Xu J; Teisan S; Chao TH; Deyanat-Yazdi G; Neuteboom ST; Lam KS; Potts BC
    J Nat Prod; 2007 Feb; 70(2):269-76. PubMed ID: 17243724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (Immuno)proteasomes as therapeutic target in acute leukemia.
    Cloos J; Roeten MS; Franke NE; van Meerloo J; Zweegman S; Kaspers GJ; Jansen G
    Cancer Metastasis Rev; 2017 Dec; 36(4):599-615. PubMed ID: 29071527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.